Evidence map›Paper›PMID 40632318›Full record

ArticleJournal of computer-aided molecular design2025

Disrupting tuberculosis pathogenesis by targeting DprE1 in cell wall biosynthesis: a structural dynamics perspective.

Abdulwahab Alamri, Ahmed Alafnan, Weiam A Hussein, Khaled Almansour, Alrafidi Rafidi Dhham, Amr S Abouzied

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of computer-aided molecular design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Abdulwahab AlamriDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Ha'il, Ha'il, Saudi Arabia.
Ahmed AlafnanDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Ha'il, Ha'il, Saudi Arabia.
Weiam A HusseinDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of Hail, Hail, 81442, Saudi Arabia.
Khaled AlmansourDepartment of Pharmaceutics, College of Pharmacy, University of Ha'il, Ha'il, Saudi Arabia.
Alrafidi Rafidi DhhamMOI Clinics, Security Forces Hospital, Riyadh, Saudi Arabia.
Amr S AbouziedDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of Hail, Hail, 81442, Saudi Arabia. as.ibrahim@uoh.edu.sa.

Funding

University of Hail RG-23 107
6 · The paper itself

Abstract

Mycobacterium tuberculosis (Mtb), the causative agent of TB, remains a major global health challenge due to the emergence of MDR and XDR strains. Targeting DprE1, an enzyme essential in the biosynthesis of the mycobacterial cell wall, offers a promising therapeutic strategy. The current work utilized a computational pipeline for identifying potential inhibitors of DprE1 from the Diverse-lib database by virtual screening, molecular docking, molecular dynamics, free binding energy calculation, and free energy landscape analysis based on RMSD and Rg values. Three candidates were identified as promising inhibitors out of all the screened diverse-lib compounds. Their binding poses and interaction patterns were analyzed and compared with those of a known reference inhibitor. In molecular docking, three compounds showed high binding affinities, while MD simulations further showed stable protein-ligand complexes for more than 300 nsec in quadruplicate. Free binding energy calculation through MM/GBSA revealed energetically favorable interactions. From this RMSD-Rg-based free energy landscape, the stability in conformation was indicated in the complexes. Minima structures also strongly agreed with initial poses, evidenced by superimposition analysis. Comparison with the reference molecule revealed that the identified compounds exhibit comparable or higher binding energies and structural stability, suggesting their potential to inhibit DprE1. These findings warrant further experimental validation to confirm their efficacy against Mtb.

Indexed as

Antitubercular AgentsBacterial ProteinsCell WallMycobacterium tuberculosisPeptidylprolyl IsomeraseTuberculosisAlcohol OxidoreductasesBinding SitesLigandsMolecular Docking SimulationMolecular Dynamics SimulationProtein BindingThermodynamicsAlcohol OxidoreductasesAntitubercular AgentsBacterial ProteinsDprE1 protein, Mycobacterium tuberculosisLigandsPeptidylprolyl IsomeraseDprE1InhibitorsMD simulationsTuberculosis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.